Precigen Announces Study Data For PRGN-2012 For Recurrent Respiratory Papillomatosis Patients; Phase 1/2 Pivotal Study Met Primary And Efficacy Endpoints
Portfolio Pulse from Benzinga Newsdesk
Precigen announced that its Phase 1/2 study for PRGN-2012 in treating Recurrent Respiratory Papillomatosis (RRP) met primary safety and efficacy endpoints. The study showed significant reductions in surgical interventions and durable complete responses in patients. PRGN-2012 was well-tolerated and induced strong immunological responses. A rolling BLA submission is anticipated in the second half of 2024.
June 03, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Precigen's PRGN-2012 met primary safety and efficacy endpoints in a Phase 1/2 study for RRP, showing significant reductions in surgical interventions and durable complete responses. The treatment was well-tolerated and induced strong immunological responses. A rolling BLA submission is anticipated in the second half of 2024.
The positive results from the Phase 1/2 study, including significant reductions in surgical interventions and durable complete responses, position PRGN-2012 as a potentially preferred treatment for RRP. The anticipation of a rolling BLA submission under an accelerated approval pathway in the second half of 2024 further boosts investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100